Application of lobaplatin in preparing medicines for treating malignant trophoblastic tumor

A technology of trophoblasts and tumor drugs, applied in the direction of anti-tumor drugs, drug combination, drug delivery, etc., can solve the problem of no malignant trophoblastic tumor treatment effect

Inactive Publication Date: 2017-07-25
GUIZHOU YIBAI PHARMA CO LTD
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although previous studies have shown that lobaplatin can be used to prepare and treat various diseases such as breast cancer, small cell lung cancer, and chroni

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lobaplatin in preparing medicines for treating malignant trophoblastic tumor
  • Application of lobaplatin in preparing medicines for treating malignant trophoblastic tumor
  • Application of lobaplatin in preparing medicines for treating malignant trophoblastic tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Study on the activity of lobaplatin against trophoblast tumor cells in vitro

[0018] 1.1 Materials and reagents

[0019] 1.1.1 Drug name and source: Lobaplatin is white freeze-dried powder, Hainan Chang’an International Pharmaceutical Co., Ltd.; carboplatin is white powder, Kunming Guiyan Pharmaceutical Co., Ltd.; 5-fluorouracil, Xi’an Haixin Pharmaceutical Co., Ltd.; cisplatin It is yellow powder, Jiangsu Hansoh Pharmaceutical Co., Ltd.

[0020] Preparation method: the above drugs are formulated with corresponding concentrations in serum-free medium.

[0021] 1.1.2 Cell lines

[0022] Human trophoblastic tumor JEG-3 cells and JAR cells were purchased from the State Key Laboratory of Family Planning and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, and cultured according to the instructions provided.

[0023] 1.1.3 Reagents and instruments

[0024] DMEM / F12 (1:1) medium, fetal bovine serum (Gibco, USA), penicillin (100u / L), str...

example 2

[0041] Trial Example 2: Study on In vivo Curative Effect of Lobaplatin on Trophoblastic Tumor

[0042] 2.1 Materials and reagents:

[0043]2.1.1 Drug name and source: Lobaplatin is white freeze-dried powder, Hainan Changan International Pharmaceutical Co., Ltd.; carboplatin is white powder, Kunming Guiyan Pharmaceutical Co., Ltd.; 5-fluorouracil, Xi’an Haixin Pharmaceutical Co., Ltd.; cisplatin It is yellow powder, Jiangsu Hansoh Pharmaceutical Co., Ltd.

[0044] 2.1.2 Experimental animals and cells

[0045] SCID beige female mice (3-5 weeks old, body weight 16-20g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.; human trophoblastic tumor cell line JAR was purchased from the American Standard Biological Collection (ATCC ), lentiviral empty vector GV208, element sequence: Ubi-MCS-EGFP, eukaryotic resistance: puromycin, fluorescent marker: EGFP, purchased from Jikai Gene, Shanghai; Polybrene was purchased from Shanghai Jikai Company.

[004...

Embodiment 3

[0066] Example 3: Clinical trials of lobaplatin in the treatment of malignant trophoblastic tumors

[0067] 3.1 Case selection: Through the clinical diagnosis of typical symptoms of malignant trophoblastic tumor, combined with HCG (human chorionic gonadotropin) detection, B-ultrasound and CT and other examinations, the patients with a definite diagnosis of malignant trophoblastic tumor were screened out 15 cases, according to UICC TNM staging, 5 cases were in stage III and 10 cases were in stage IV. All patients had a KPS score greater than 60. 15 patients were randomly divided into two groups, 8 cases in the treatment group, all female, aged 26-45 years, with an average age of 34.3 years, 2 cases in stage III, 6 cases in stage IV; 6 cases in the control group, all female, age 23-47 years old, with an average age of 35.9 years, 3 cases were in stage III, and 4 cases were in stage IV. The two groups were comparable in terms of age, gender, disease duration, and condition. Be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of lobaplatin in preparing medicines for treating malignant trophoblastic tumor. The lobaplatin is represented in dosage forms of lyophilized powder for injection, a small -volume injection or a large-volume injection, with an effective therapeutic dose of 30-60mg/m<2> body surface area. The lobaplatin and a preparation thereof are relatively strong in action of resisting the malignant trophoblastic tumor; and the lobaplatin and the preparation thereof are significant in therapeutic effect, low in toxicity and safe; therefore, a novel effective means is provided for the treatment of the malignant trophoblastic tumor and clinical application of the lobaplatin and the preparation thereof is widened.

Description

technical field [0001] The invention relates to a new application of lobaplatin, in particular to an application of lobaplatin in the preparation of medicines for treating malignant trophoblastic tumors. [0002] technical background [0003] Malignant trophoblastic tumor is the malignant transformation of embryonic trophoblastic cells. Such tumors include invasive mole, choriocarcinoma and placental site trophoblastic tumor, and choriocarcinoma includes gestational choriocarcinoma and non-gestational choriocarcinoma. Sexual choriocarcinoma is rare, but can occur in retroperitoneal mediastinum, ovary, lung, esophagus, stomach, liver, pelvic cavity, etc. The etiology of trophoblasts is unclear, and may be related to malnutrition (especially lack of high-quality animal protein diet), viral infection, ovarian dysfunction and egg abnormalities, chromosomal abnormalities, immune function abnormalities, race, geography, climate and environmental influences. Malignant trophoblastic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/282A61K9/19A61P35/00
CPCA61K33/24A61K9/0019A61K9/19A61K31/282A61K2300/00
Inventor 窦啟玲隋东虎张圣贵
Owner GUIZHOU YIBAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap